Repositorio UFRO · Omeka S

Evaluation of trefoil factor 3 as a non-invasive biomarker of gastric intestinal metaplasia and gastric cancer in a high-risk population

Primer Autor	Riquelme, Arnoldo
Co-autores	Latorre, Gonzalo Pizarro, Margarita Ford, James Stephen Gandara, Vicente Munoz, Gonzalo Araya, Juan Carlos Bellolio, Enrique Villaseca, Miguel Fuentes-Lopez, Eduardo Cortes, Pablo Rollan, Antonio Bufadel, Maria Ester Araya, Raul Vargas, Jose Ignacio Espino, Alberto Sharp, Allan Aguero, Carlos Donoso, Andres Bresky, Gustavo Pedrero, Pamela Rueda, Carlos Calvo, Alfonso Odagaki, Tomoyuki Moriyama, Tomohiko Ishida, Tsukasa Parra-Blanco, Adolfo Camargo, M. Constanza Gonzalez, Robinson Corvalan, Alejandro H.
Título	Evaluation of trefoil factor 3 as a non-invasive biomarker of gastric intestinal metaplasia and gastric cancer in a high-risk population
Editorial	ELSEVIER ESPANA SLU
Revista	GASTROENTEROLOGIA Y HEPATOLOGIA
Lenguaje	en
Resumen	Background: Adenocarcinoma is preceded by chronic atrophic gastritis, gastric intestinal meta-plasia and dysplasia. Trefoil factor 3 (TFF3) is a peptide secreted by goblet cells, which is abundantly present in intestinal metaplasia. Aim: To evaluate the utility of serum TFF3 as a non-invasive biomarker for the diagnosis of intestinal metaplasia and gastric cancer. Methods: Single-center, cross-sectional study of 274 patients who consecutively underwent upper gastrointestinal endoscopy with gastric biopsies (updated Sydney system). TFF3 levels were measured in serum by a commercial ELISA kit. Patients with normal histology or chronic atrophic gastritis without intestinal metaplasia comprised the control group. In addition, 14 patients with invasive gastric cancer were included as a reference group. The association between TFF3 levels and intestinal metaplasia was assessed by logistic regression. Results: Patients with intestinal metaplasia (n = 110) had a higher median TFF3 level as com-pared to controls (n = 164), 13.1 vs. 11.9 ng/mL, respectively (p = 0.024). Multivariable logistic regression showed a no significant association between TFF3 levels and intestinal metaplasia (OR = 1.20, 95%CI: 0.87-1.65, p-trend = 0.273). The gastric cancer group had a median TFF3 level of 20.5 ng/mL, and a significant association was found (OR = 3.26, 95%CI: 1.29-8.27, p-trend = 0.013). Conclusion: Serum levels of TFF3 do not discriminate intestinal metaplasia in this high-risk Latin American population. Nevertheless, we confirmed an association between TFF3 levels and invasive gastric cancer. (c) 2022 Elsevier Espan similar to a, S.L.U. All rights reserved.
Fecha Publicación	2023
Tipo de Recurso	artículo original
doi	10.1016/j.gastrohep.2022.04.004
Formato Recurso	PDF
Palabras Claves	Trefoil factor 3 Gastric cancer Precancerous conditions Intestinal metaplasia
Ubicación del archivo	http://dx.doi.org/10.1016/j.gastrohep.2022.04.004
Categoría OCDE	Gastroenterología y Hepatología
Materias	factor de trébol 3 Cáncer gástrico Condiciones precancerosas Metaplasia intestinal
Página de inicio (Recomendado-único)	411.0
Página final (Recomendado-único)	418
Identificador del recurso (Mandatado-único)	artículo original
Versión del recurso (Recomendado-único)	versión publicada
Derechos de acceso	metadata
Access Rights	metadata
Id de Web of Science	WOS:001005226100001
ISSN	0210-5705
Tipo de ruta	hibrida
Categoría WOS	Gastroenterología y Hepatología
Referencia del Financiador (Mandatado si es aplicable-repetible)	CONICYT-FONDAP 15130011 ANID-FONDECYT 1151411 ANID CONICYT-FONDAP 15130011 ANID FONDECYT 1151411